Kodiak Sciences Inc. Notes to Consolidated Financial Statements 92 Manufacturing Agreements The Company has entered into service and equipment purchase agreements in the normal course of business with various providers, pursuant to which such providers agreed to perform activities in connection with the manufacturing process of certain materials. These agreements, and any related amendments, state that planned activities and purchases that are included in the signed work orders are, in some cases, binding and, hence, obligate the Company to pay the full price of the work order upon satisfactory delivery of products and services or obligate the Company to the binding amount regardless of whether such planned activities are in fact performed. Per the terms of the agreements, the Company has the option to cancel signed orders at any time upon written notice, which may or may not be subject to payment of a cancellation fee. The level of cancellation fees may be dependent on the timing of the written notice in relation to the commencement date of the work, with the maximum cancellation amount dependent on the agreement or the work order. As of December 31, 2025, future contractual obligations related to these manufacturing agreements that may be subject to cancellation fees was $23.9 million. This amount represents our minimal contractual obligations, excluding the commitments under the Ursus Facility arrangement. Purchases under these manufacturing agreements for the years ended December 31, 2025, 2024 and 2023 were $34.8 million, $25.8 million and $59.7 million, respectively. In addition, future manufacturing contractual obligations totaling approximately 86.5 million Swiss Francs may be incurred for the potential clinical and commercial supply of tarcocimab and other antibody biopolymer conjugates medicines based on the agreements with Lonza for production at the Ursus Facility. Other Funding Commitments In the normal course of business, the Company enters into agreements with third-parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company. The Company has also entered into various cancellable license agreements for certain technology. The Company may be obligated to make payments on future sales of specified products associated with such license agreements. Such payments are dependent on future product sales and are not estimable. Legal Proceedings From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Management is currently not aware of any matters that could have a material adverse effect on the its financial position, results of operations or cash flows. The Company records a legal liability when it believes that it is both probable that a liability may be imputed, and the amount of the liability can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the estimated amount. 9. Income Taxes The components of loss before income taxes were as follows (in thousands): Year Ended December 31, 2025 2024 2023 ........................................................................................... United States $ (154,535) $ (118,783) $ (143,256) .................................................................................................... Foreign (75,380) (57,404) (117,176) .............................................................. Total loss before income taxes $ (229,915) $ (176,187) $ (260,432) For the years ended December 31, 2025, 2024, and 2023, the Company recorded $52 thousand, $20 thousand, and $33 thousand of foreign current income tax expense, respectively. Income taxes paid, net of refunds received, were not material for the years ended December 31, 2025, 2024, and 2023.